Selecting Sensitive Chemotherapeutic Drugs Based On The Genetic Testing In The Application Of The Esophagogastric Junction Carcinoma Treatment

Esophagogastric Junction Carcinoma is one of the most malignant types of cancer.It’s reproted in home and abroad The incidence of esophagogastric junction carcinoma presents a abviously rising trend,and esophagogastric junction carcinoma has been one of the speediest development malignant tumors.the prognosis of patients with esophagogastric junction carcinoma is poor.It was not obviosly improved that the patients were treated by emprical using the chemotherapy drugs before.With the further study of molecular biology,Hope that the patients’ suvival rate will be improved,who will be treated with sensitive anticancer drugs by genetic testing.Consulting lots of reference found: Excision Repair Cross Complementing gene 1(ERCC1)participate in a variety of tumor initiation and progression.Among the advanced cancer patients treated with platinum-based chemotherapy,Platinum-DNA adduct clould induce ERCC1 to be high expression,then lead to the resistence of platinum drug.Thymidylate synthase(TYMS)express in a variety of tumors.Fluorine chemotherapy drugs are sensitive when the TYMS is low expression.The lower the expression is,the better the prognosis is.The expression is associated with the progression of tumor such as the TNM stages,but the ClassⅢβ-tubulin(TUBB3)also express in mang different tumors.Its lower expression is positive correlation with medicinal cure ceffcet of taxanes,it is not ralated to gender、age,but with the progression of tumor,it usually presents high expression.Human epidermal growth factor receptor type 2(Her2)is associated with metastasis and invasion of mang different tumors,but not associated with gender、age and so on.The over expression of Her2 is positive correlation with malignant degree,and clould lead to resiste of some traditional drug.antibody-drug conjugate’application has abtained considerable effect.These genes is rarely reproted in the treatment of esophagogastric junction carcinoma.Expecting that individualized chemotherapy improves prognosis and increase survival rate.